Second-generation antipsychotic medications in the treatment of mood disorders

Focus on aripiprazole

Peter F Buckley

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Second-generation antipsychotic medications offer a broader range of therapeutic efficacies than first-generation agents. Consequently, our field has witnessed a rapid expansion of the use of second-generation antipsychotic drugs for several conditions beyond psychosis. The use of second-generation antipsychotic medications has been most pronounced in mood disorders, especially in bipolar disorders. Information about the agents clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole in terms of their efficacy and tolerability in bipolar disorder is now available. Aripiprazole, a new agent whose proposed mechanism(s) of action differs from that of other agents, has been shown in placebo-controlled comparative trials in bipolar patients to be an effective and well tolerated treatment option for this patient group. The role of second-generation antipsychotic medications in the therapeutic armamentarium for bipolar disorders will be determined by clinical experience, by additional phase IV studies and by trials that compare second-generation antipsychotics with each other and also with mood-stabilizing medications. There is also a pressing need for additional information on the long-term efficacy and safety of each second-generation antipsychotic agent during maintenance therapy for bipolar disorders.

Original languageEnglish (US)
Pages (from-to)5-11
Number of pages7
JournalDrugs of Today
Volume41
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Mood Disorders
Antipsychotic Agents
Bipolar Disorder
olanzapine
Therapeutics
Risperidone
Clozapine
Psychotic Disorders
Aripiprazole
Placebos
Safety

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Second-generation antipsychotic medications in the treatment of mood disorders : Focus on aripiprazole. / Buckley, Peter F.

In: Drugs of Today, Vol. 41, No. 1, 01.01.2005, p. 5-11.

Research output: Contribution to journalReview article

@article{3cb888ebccb140a88f6729536ab75c88,
title = "Second-generation antipsychotic medications in the treatment of mood disorders: Focus on aripiprazole",
abstract = "Second-generation antipsychotic medications offer a broader range of therapeutic efficacies than first-generation agents. Consequently, our field has witnessed a rapid expansion of the use of second-generation antipsychotic drugs for several conditions beyond psychosis. The use of second-generation antipsychotic medications has been most pronounced in mood disorders, especially in bipolar disorders. Information about the agents clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole in terms of their efficacy and tolerability in bipolar disorder is now available. Aripiprazole, a new agent whose proposed mechanism(s) of action differs from that of other agents, has been shown in placebo-controlled comparative trials in bipolar patients to be an effective and well tolerated treatment option for this patient group. The role of second-generation antipsychotic medications in the therapeutic armamentarium for bipolar disorders will be determined by clinical experience, by additional phase IV studies and by trials that compare second-generation antipsychotics with each other and also with mood-stabilizing medications. There is also a pressing need for additional information on the long-term efficacy and safety of each second-generation antipsychotic agent during maintenance therapy for bipolar disorders.",
author = "Buckley, {Peter F}",
year = "2005",
month = "1",
day = "1",
doi = "10.1358/dot.2005.41.1.875774",
language = "English (US)",
volume = "41",
pages = "5--11",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Second-generation antipsychotic medications in the treatment of mood disorders

T2 - Focus on aripiprazole

AU - Buckley, Peter F

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Second-generation antipsychotic medications offer a broader range of therapeutic efficacies than first-generation agents. Consequently, our field has witnessed a rapid expansion of the use of second-generation antipsychotic drugs for several conditions beyond psychosis. The use of second-generation antipsychotic medications has been most pronounced in mood disorders, especially in bipolar disorders. Information about the agents clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole in terms of their efficacy and tolerability in bipolar disorder is now available. Aripiprazole, a new agent whose proposed mechanism(s) of action differs from that of other agents, has been shown in placebo-controlled comparative trials in bipolar patients to be an effective and well tolerated treatment option for this patient group. The role of second-generation antipsychotic medications in the therapeutic armamentarium for bipolar disorders will be determined by clinical experience, by additional phase IV studies and by trials that compare second-generation antipsychotics with each other and also with mood-stabilizing medications. There is also a pressing need for additional information on the long-term efficacy and safety of each second-generation antipsychotic agent during maintenance therapy for bipolar disorders.

AB - Second-generation antipsychotic medications offer a broader range of therapeutic efficacies than first-generation agents. Consequently, our field has witnessed a rapid expansion of the use of second-generation antipsychotic drugs for several conditions beyond psychosis. The use of second-generation antipsychotic medications has been most pronounced in mood disorders, especially in bipolar disorders. Information about the agents clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole in terms of their efficacy and tolerability in bipolar disorder is now available. Aripiprazole, a new agent whose proposed mechanism(s) of action differs from that of other agents, has been shown in placebo-controlled comparative trials in bipolar patients to be an effective and well tolerated treatment option for this patient group. The role of second-generation antipsychotic medications in the therapeutic armamentarium for bipolar disorders will be determined by clinical experience, by additional phase IV studies and by trials that compare second-generation antipsychotics with each other and also with mood-stabilizing medications. There is also a pressing need for additional information on the long-term efficacy and safety of each second-generation antipsychotic agent during maintenance therapy for bipolar disorders.

UR - http://www.scopus.com/inward/record.url?scp=15344338978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15344338978&partnerID=8YFLogxK

U2 - 10.1358/dot.2005.41.1.875774

DO - 10.1358/dot.2005.41.1.875774

M3 - Review article

VL - 41

SP - 5

EP - 11

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 1

ER -